Keeping you up to date on recent developments in neurology, including: Genetic analysis of symptoms yields new insights into PTSD; AI used to predict schizophrenia in relatives of patients; Growth factors linked to lysosomes, Parkinson’s risk; Study links ALS gene to tumor suppressor, transcription changes.
A packaged nanoparticle that delivered a relaxin-encoding gene therapy with microRNA reduced liver fibrosis, researchers in the laboratory of Leaf Huang at the University of North Carolina, Chapel Hill, Eshelman School of Pharmacy described in the Jan. 21, 2021, issue of Nature Nanotechnology.
Keeping you up to date on recent developments in diagnostics, including: Diagnosing myotonia; Lumbar spine MRI interpretation; Gray matter damage in MS starts at synapses.
A study led by scientists at the University of Science and Technology of China in Hefei City is the first to show that astrocytic apolipoprotein E (ApoE) regulates neuronal epigenetic states via reprogramming lipid metabolism, which was shown to control brain function, in particular memory consolidation, in mice.
Keeping you up to date on recent developments in orthopedics, including: Scientists use a novel ink to 3D print 'bone' with living cells; Student uses zebrafish to study spinal deformities; A compound that slows bone loss, and a resource for developing treatments to slow aging.
An Australian-led study reported in the January 25, 2021, online edition of NatureImmunology has identified a new immunomodulatory pathway within the gut-lung axis that enhances microbial tyrosine metabolism, which could be targeted to treat or prevent atopic asthma and other inflammatory diseases.
Keeping you up to date on recent developments in oncology, including: Hypoxia a potential marker for recurrent glioblastoma; SCLC subtypes have specific vulnerabilities; Few-shot learning may speed up drug development; New research may move up breast cancer diagnosis.
An international study led by Australian scientists has shown for the first time that the androgen receptor (AR) is a tumor suppressor in estrogen receptor-positive (ER+) metastatic breast cancer, including in endocrine therapy resistance, which supports the use of an AR agonist-based treatment strategy.
Keeping you up to date on recent developments in cardiology, including: Age influences sex-related outcomes following a heart attack; Fried food intake fingered in upped risk of heart disease, stroke; Genetic risk factor for stroke revealed.
RSS
